Advertisement
Advertisement
GRCE
Grace Therapeutics, Inc. Common Stock
3.56
USDSponsored
+0.08
+2.44%
Feb 06, 15:59 UTC -5
Closed
After-Market
3.60
+0.03
+0.84%
GRCE Earnings Reports
Positive Surprise Ratio
GRCE beat 14 of 22 last estimates.
64%
Next Report
Date of Next Report
Feb 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.28
Implied change from Q2 26 (Revenue/ EPS)
--
/+366.67%
Implied change from Q3 25 (Revenue/ EPS)
--
/+7.69%
Grace Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, GRCE reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.18 USD, resulting in a 68.20% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.28 USD, with revenue projected to reach -- USD, implying an increase of 366.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Grace Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Grace Therapeutics, Inc. Common Stock reported EPS of -$0.06, beating estimates by 68.2%, and revenue of $0.00, 0% as expectations.
How did the market react to Grace Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.31%, changed from $3.03 before the earnings release to $3.10 the day after.
When is Grace Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 16, 2026.
What are the forecasts for Grace Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Grace Therapeutics, Inc. Common Stock is expected to report EPS of -$0.28 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement